When expressed via Sox2-Cre it promotes eRMS-induction in a Tp53−/+ (100% penetrance/20 weeks median latency, 50% of tumors are eRMS), but not Tp53−/−-background (100% penetrance/27 weeks median latency, mostly lymphoma, no eRMS. The gene discussed is TP53; the disease is lymphoma.